12 results about "Cytokine secretion" patented technology

The application provides an active exosome stent coating, a vascular stent and a preparation method and application, and belongs to the technical field of biomedical intervention instruments. The active exosome stent coating of the application adopts stem cell-derived myocardial cell active exosomes which are strengthened by active components of traditional Chinese medicine. Compared with commercial myocardial cells, the stem cell-derived myocardial cells have more significant effects of promoting blood vessels and tissue repair and regeneration, and stronger cytokine secretion capacity. The preparation method of the active exosome stent coating of the application adjusts the introduction sequence and premixing mode of active components such as exosomes and drugs, and enhances the homogeneity and stability. The vascular stent prepared by using the active exosome stent coating of the application has reasonable sequential release kinetics design, can realize precise targeted regulation on human coronary artery smooth muscle cells (HCASMC) in vitro, does not affect the repair potential of endothelial cells, and solves the contradiction between traditional stents in terms of "anti-proliferation and promotion of healing".

This invention belongs to the field of biomedical technology, specifically relating to a method and application for preparing CAR-T cells with enhanced persistence based on the piggyBac transposon system combined with electroporation. This invention, through specific piggyBac dual plasmid ratios and electroporation conditions, can improve transfection efficiency to over 80%, and the integration site is more likely to be located in a safe genomic region, supporting long-term stable CAR expression. Furthermore, cell expansion kinetics are significantly improved, with expansion exceeding 120-fold within 15 days. The results of the examples show that CAR-T cells prepared using the method described in this invention exhibit significantly enhanced tumor cell killing ability and cytokine secretion levels in in vitro models, and are rich in memory T cell subsets (Tcm / Tem) with greater persistence and self-renewal potential. This indicates that this invention not only changes the method of gene delivery but also shapes the intrinsic properties of cells, enabling them to acquire potentially superior in vivo persistence and long-term anti-tumor capabilities.

A cell expressing a fusion protein and its applications. This cell possesses enhanced capabilities, such as cell proliferation, cytokine secretion, and tumor cell killing.

Provided herein are chimeric antigen receptors, comprising an extracellular domain capable of binding to an antigen, an Fc region, a flexible linker, a transmembrane domain, and may further comprise at least one intracellular domain that is designed to increase the anti-tumor activities of granulocytes, macrophages, and dendritic cells by increasing their phagocytosis and / or proinflammatory cytokines secretion and / or antigen presentation. Provided herein are vectors and nucleic acid molecules encoding any of the chimeric antigen receptors described herein. Provided herein are methods to genetically engineer granulocyte-macrophage progenitors (GMPs) to express the chimeric antigen receptors described herein. The CAR-Fc-GMPs may be induced to differentiate into macrophages or granulocytes. Provided herein are macrophages and granulocytes that express a CAR-Fc prepared by any of the methods described herein. Provided herein is an immunotherapy method for treating a subject having cancer with GMPs or macrophages or granulocytes that express the chimeric antigen receptors described herein.

Disclosed herein are fluidic devices that facilitate gas diffusion between biological samples and gas-filled compartments or an external atmosphere to stabilize dissolved gas levels within the biological samples. The fluidic devices can include a gas-permeable spacer separating the biological sample-containing channel from the gas-filled compartments or external atmosphere to facilitate rapid gas exchange within the biological sample. Further disclosed herein are methods of using the fluidic devices to incubate and determine characteristics of the samples, including methods for measuring cytokine secretion from individual cells.

The application provides an enhanced CAR-T cell overexpressing CD200 and an application thereof, and belongs to the technical field of biological medicine. The application provides an application of CD200 in preparation of a product for improving the anti-tumor effect of a CAR-T cell. CD200 can improve the cytokine secretion capacity of a CAR-T cell, thereby improving the killing and anti-tumor effect of the CAR-T cell. The application overexpresses CD200 on a CD19 CAR-T cell, and compared with a conventional CD19 CAR-T cell, has stronger cytokine secretion capacity, and can better play the killing and anti-tumor function.

The application discloses a new application of m6A modified gene GAS6 and its receptor MERTK in rheumatoid arthritis. Multi-omics integrated analysis of synovial tissue and peripheral blood mononuclear cells of RA patients reveals common dysregulation of transcriptomics and epitranscriptomics, highlighting genes with both differential expression and m6A modification, which are enriched in processes such as phagocytosis, Th17 differentiation and cell aging. Among these genes, GAS6 shows the most significant m6A hypermethylation and expression up-regulation, and is verified as a key effector molecule interacting with MERTK / AXL receptor. Functional experiments show that GAS6 and MERTK synergistically promote the malignant phenotype of RA fibroblast-like synoviocytes, enhance their proliferation, migration, inflammatory cytokine secretion and anti-apoptotic ability.

A cell expressing a multispecific antigen-binding protein and its applications are provided. This cell possesses enhanced capabilities, such as cell proliferation, cytokine secretion, and tumor cell killing.

The application discloses a double-target chimeric antigen receptor T cell, a preparation method and application, and relates to the technical field of medicine, in particular to a double-target chimeric antigen receptor T cell which is a T cell simultaneously expressing a targeting mesothelin chimeric antigen receptor and a targeting fibroblast activation protein chimeric antigen receptor. The double-target chimeric antigen receptor T cell can break through the surface barrier of a solid tumor, enhance direct killing of the tumor and promote cytokine secretion, and can effectively overcome the limitations of existing chimeric antigen receptor T cells in the application of solid tumors. The preparation method provided by the application can obtain the double-target chimeric antigen receptor T cell which can simultaneously and evenly express the two chimeric antigen receptors through an optimized transduction and expansion culture process, and the double-target chimeric antigen receptor T cell has a high CAR double-positive rate, good cell activity and strong freeze-thaw stability. The preparation method can meet the GMP requirement and has excellent clinical transformation potential.

The application relates to a preparation and application of a chimeric antigen receptor targeting BCMA. The immunogenicity of scFv is significantly reduced by humanizing the mouse-derived antibody, and the human anti-mouse antibody (HAMA) reaction can be reduced, and the persistence and safety of CAR-T cells in the patient body can be improved. The affinity (KD approximately 1.46E-07 M) of the preferred scFv (such as D12.u21) obtained by the application to BCMA is reduced by about 10,000 times compared with that of a commercial high-affinity scFv (C11D5.3, KD approximately 1.09E-11 M). The "medium-low" affinity characteristic aims to balance the activation strength of CAR-T cells and avoid T cell exhaustion caused by excessive activation. Although the affinity is greatly reduced, the CAR-T cells expressing the preferred scFv (D12.u21) of the application show better killing effect than the high-affinity control (C11D5) CAR-T cells in in-vitro experiments. Under a higher target ratio, the killing efficiency and IFN-gamma cytokine secretion level of the CAR-T cells are both significantly higher, indicating that the CAR-T cells have stronger effector function and activation potential.

Idiopathic Parkinson's disease (iPD) is a multi-system disorder, and the debilitating motor stage of iPD can be preceded for years by a prodromal stage characterized by non-motor symptoms like REM sleep behavior disorder (RBD) and gastrointestinal symptoms. Widespread immune dysregulation has been reported in clinically diagnosed iPD, but the existence of immune deficits during the prodromal stage has yet to be thoroughly investigated. Here, it was shown that multiple stages of iPD, including the pre-motor prodromal stage, can be stratified according to the immuno-metabolic response to stimulation of peripheral blood immune cells ex vivo. Peripheral blood monocytes from RBD patients displayed increased stimulation-dependent secretion of inflammatory cytokines, including TNF, IL-1β, and IL-8, which peaks in the prodromal stage and successively diminishes as PD progresses. Furthermore, T lymphocyte mitochondrial health was correlated with stimulation-evoked cytokine secretion across patients with RBD, early-stage iPD, and moderate-stage iPD. The results disclosed here have broad implications for mechanistic understanding of how peripheral inflammation may drive disease progression, and it reveals novel biomarkers to enable patient stratification and progression monitoring for clinical trials based on immune endophenotypes.